Literature DB >> 12239306

Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

James Lue1, Mayla Hsu, David Yang, Preston Marx, Zhiwei Chen, Cecilia Cheng-Mayer.   

Abstract

The potential role of dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) binding in human immunodeficiency virus transmission across the mucosal barrier was investigated by assessing the ability of simian-human immunodeficiency chimeric viruses (SHIVs) showing varying degrees of mucosal transmissibility to bind the DC-SIGN expressed on the surface of transfected cells. We found that gp120 of the highly transmissible, pathogenic CCR5-tropic SHIV(SF162P3) bound human and rhesus DC-SIGN with an efficiency threefold or greater than that of gp120 of the nonpathogenic, poorly transmissible parental SHIV(SF162), and this increase in binding to the DC-SIGN of the SHIV(SF162P3) envelope gp120 translated into an enhancement of T-cell infection in trans. The presence of an additional glycan at the N-terminal base of the V2 loop of SHIV(SF162P3) gp120 compared to that of the parental virus was shown to be responsible for the increase in binding to DC-SIGN. Interestingly, this glycan also conferred escape from autologous neutralization, raising the possibility that the modification occurred as a result of immune selection. Our data suggest that more-efficient binding of envelope gp120 to DC-SIGN could be relevant to the enhanced mucosal transmissibility of SHIV(SF162P3) compared to that of parental SHIV(SF162).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239306      PMCID: PMC136558          DOI: 10.1128/jvi.76.20.10299-10306.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.

Authors:  T B Geijtenbeek; D S Kwon; R Torensma; S J van Vliet; G C van Duijnhoven; J Middel; I L Cornelissen; H S Nottet; V N KewalRamani; D R Littman; C G Figdor; Y van Kooyk
Journal:  Cell       Date:  2000-03-03       Impact factor: 41.582

Review 2.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

Authors:  P W Parren; J P Moore; D R Burton; Q J Sattentau
Journal:  AIDS       Date:  1999       Impact factor: 4.177

3.  Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques.

Authors:  P A Luciw; C P Mandell; S Himathongkham; J Li; T A Low; K A Schmidt; K E Shaw; C Cheng-Mayer
Journal:  Virology       Date:  1999-10-10       Impact factor: 3.616

4.  Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells.

Authors:  J A LaBonte; T Patel; W Hofmann; J Sodroski
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells.

Authors:  J Hu; M B Gardner; C J Miller
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.

Authors:  A Ly; L Stamatatos
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo.

Authors:  B Etemad-Moghadam; Y Sun; E K Nicholson; M Fernandes; K Liou; R Gomila; J Lee; J Sodroski
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells.

Authors:  A Granelli-Piperno; E Delgado; V Finkel; W Paxton; R M Steinman
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

9.  Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid.

Authors:  S S Frankel; B M Wenig; A P Burke; P Mannan; L D Thompson; S L Abbondanzo; A M Nelson; M Pope; R M Steinman
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

10.  Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells.

Authors:  M Pope; S Gezelter; N Gallo; L Hoffman; R M Steinman
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  24 in total

1.  Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.

Authors:  Mayla Hsu; Janet M Harouse; Agegnehu Gettie; Clarisa Buckner; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  CHARMM additive all-atom force field for carbohydrate derivatives and its utility in polysaccharide and carbohydrate-protein modeling.

Authors:  Olgun Guvench; Sairam S Mallajosyula; E Prabhu Raman; Elizabeth Hatcher; Kenno Vanommeslaeghe; Theresa J Foster; Francis W Jamison; Alexander D Mackerell
Journal:  J Chem Theory Comput       Date:  2011-10-11       Impact factor: 6.006

3.  Envelope variation as a primary determinant of lentiviral vaccine efficacy.

Authors:  Jodi K Craigo; Baoshan Zhang; Shannon Barnes; Tara L Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

4.  The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.

Authors:  Cheryl J Saunders; Ruth A McCaffrey; Irina Zharkikh; Zane Kraft; Susan E Malenbaum; Brian Burke; Cecilia Cheng-Mayer; Leonidas Stamatatos
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells.

Authors:  Kabamba B Alexandre; Elin S Gray; Hazel Mufhandu; James B McMahon; Ereck Chakauya; Barry R O'Keefe; Rachel Chikwamba; Lynn Morris
Journal:  Virology       Date:  2011-12-29       Impact factor: 3.616

6.  Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants.

Authors:  Ruth Dickover; Eileen Garratty; Karina Yusim; Catherine Miller; Bette Korber; Yvonne Bryson
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.

Authors:  Emily J Platt; Danielle M Shea; Patrick P Rose; David Kabat
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

8.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission.

Authors:  Po-Jen Yen; Alon Herschhorn; Hillel Haim; Ignacio Salas; Christopher Gu; Joseph Sodroski; Dana Gabuzda
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

10.  Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Authors:  Ann J Hessell; Eva G Rakasz; Pascal Poignard; Lars Hangartner; Gary Landucci; Donald N Forthal; Wayne C Koff; David I Watkins; Dennis R Burton
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.